Adverse effects of IgG therapy

Journal of Allergy and Clinical Immunology: In Practice

Volumn 1, Issue 6, 2013, Pages 558-566

  Berger, Melvin ^a  

^a CSL Behring LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BIVIGAM; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 11A; CARIMUNE NF; CORTICOSTEROID; CYPROHEPTADINE; GAMMAKED; GAMUNEX C; GLUCOCORTICOID; GLYCINE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MALTOSE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISONE; PROLINE; SEROTONIN ANTAGONIST; SORBITOL; SUCROSE; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ARTICLE; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; AWARENESS; BURNING SENSATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG FORMULATION; DRUG LABELING; DRUG PURIFICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; HYPONATREMIA; IMMUNE DEFICIENCY; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOTHERAPY; INCIDENCE; INFLAMMATION; INFUSION RATE; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MEDICAL DECISION MAKING; MIGRAINE; NEUTROPENIA; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SKIN MANIFESTATION; THROMBOEMBOLISM; TRANSFUSION RELATED ACUTE LUNG INJURY; UNITED STATES; ACUTE KIDNEY INJURY; ANEMIA, HEMOLYTIC; HEADACHE DISORDERS; MENINGITIS, ASEPTIC; SKIN DISEASES;

ACUTE KIDNEY INJURY; ANAPHYLAXIS; ANEMIA, HEMOLYTIC; HEADACHE DISORDERS; HUMANS; HYPONATREMIA; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; MENINGITIS, ASEPTIC; NEUTROPENIA; RISK FACTORS; SKIN DISEASES; THROMBOEMBOLISM;

EID: 84887003230     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2013.09.012     Document Type: Article

References (69)

1. Orange J.S., Hossny E.M., Weiler C.R., Ballow M., Berger M., Bonilla F.A., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. JAllergy Clin Immunol 2006, 117:S525-S553.
2. Hooper J.A. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am 2008, 28:765-778.
3. Pierce L.R., Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003, 17:241-251.
4. Ballow M. Clinical and investigational considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005, 62(Suppl 3):S12-S18.
5. Silvergleid AJ, Berger M. Intravenous immune globulin: adverse effects. UpToDate, 2013. Available from:. Accessed October 8, 2013. http://www.uptodate.com.
6. Stiehm E.R. Adverse effects of human immunoglobulin therapy. Transfusion Med Rev 2013, 27:171-178.
7. Berger M., Pinciaro P.J. Flebogamma 5% Investigators. Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. JClin Immunol 2004, 24:389-396.
8. AAAAI Primary Immune Deficiency Committee. IVIG toolkit. Available from:. Accessed July 29, 2013. http://www.aaaai.org/practice-resources/Practice-Tools/ivig-toolkit.aspx.
9. Ochs H., Gupta S., Kiesling P., Nicolay U., Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. JClin Immunol 2006, 26:265-273.
10. Barandun S., Morell A., Skvaril F. Clinical experiences with immunoglobulin for intravenous use. Immunoglobulins: Characteristics and Uses of Intravenous Preparations 1980, 31-35. US Department of Health and Human Services, Washington, DC. B.M. Alving, J.S. Finlayson (Eds.).
11. Sun A., Teschner W., Yel L. Improving patient tolerability in immunoglobulin treatment: focus on stabilizer effects. Expert Rev Clin Immunol 2013, 9:577-587.
12. Hagan J.B., Wasserman R.L., Baggish J.S., Spycher M.O., Berger M., Shashi V., et al. Safety of L-proline as a stabilizer for immunoglobulin products. Expert Rev Clin Immunol 2012, 8:169-178.
13. van der Heijden J., Geissler J., van Mirre E., van Deuren M., van der Meer J., Salama A., et al. Anovel splice variant of FcgRIIa: a risk factor for anaphylaxis in patients with hypogammaglobulinemia. JAllergy Clin Immunol 2013, 131:1408-1416.
14. Singh-Grewal D., Kemp A., Wong M. Aprospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Arch Dis Child 2006, 91:651-654.
15. Debes A., Bauer M., Kremer S. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study. Pharmacoepidemiol Drug Saf 2007, 16:1038-1047.
16. Mathy I., Gille M., Van Raemdonck F., Delberg J., Depré A. Neurological complications of intravenous immunoglobulin (IVIg) therapy: an illustrative case of acute encephalopathy following IVIg therapy and a review of the literature. Acta Neurol Belg 1998, 98:347-351.
17. Finkel A.G., Howard J.F., Mann J.D. Successful treatment of headache related to intravenous immunoglobulin with antimigraine medications. Headache 1998, 38:317-321.
18. Sekul E.A., Cupler E.J., Dalakas M.C. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994, 121:259-262.
19. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004, 112:1-7.
20. Hagan J.B., Fasano M.B., Spector S., Wasserman R.L., Melamed I., Bojavin M.A., et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. JClin Immunol 2010, 30:734-745.
21. Wasserman R.L., Irani A.-M., Tracy J., Tsoukas C., Stark D., Levy R., et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol 2010, 161:518-526.
22. Wasserman R.L., Melamed I., Kobrynski L., Strausbaugh S., Stein M.R., Sharkhaury M., et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (Gammagard liquid, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. JClin immunol 2011, 31:323-331.
23. Epstein JS, Zoon KC. Important Drug Warning: potential risk of acute renal failure reported to be associated with administration of immune globulin intravenous (human). Available from:. Accessed July 29, 2013. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm105901.htm.
24. US Food and Drug Administration. FDA Safety Communication: new boxed warning for thrombosis related to human immune globulin products, June 10, 2013. Available from:. Accessed July 29, 2013. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm355986.htm.
25. US Food and Drug Administration. Guidance for industry: contraindications and boxed warning sections of labelling for human prescription drug and biological products. Available from:. Accessed July 29, 2013. http://www.fda.gov/downloads/Drugs/Guidances/ucm075096.pdf.
26. Caress J.B., Cartwright M.S., Donofrio P.D., Peacock J.E. The clinical features of 16 cases of stroke associated with administration of IVIG. Neurology 2003, 60:1822-1824.
27. Go R.S., Call T.G. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 2000, 75:83-85.
28. Katz K.A., Hivnor C.M., Geist D.E., Shapiro M., Ming M.E., Werth V.P. Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Arch Dermatol 2003, 139:991-993.
29. Rajabally Y.A., Kearney D.A. Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study. JNeurol Sci 2011, 308:124-127.
30. Caress J.B., Hobson-Webb L., Passmore L.V., Finkbeiner A.P., Cartwright M.S. Case-control study of thromboembolic events associated with IV immunoglobulin. JNeurol 2009, 256:339-342.
31. US Food and Drug Administration. Evidence for a link between an immune globulin product and thrombosis. March 2012. Available from:. Accessed July 29, 2013. http://www.fda.gov/downloads/BiologicsBloodVaccines/ScienceResearch/UCM300418.pdf.
32. Daniel G.W., Menis M., Sridhar G., Scott D., Wallace A.E., Ovanesov M.V. Immune globulins and thrombotic adverse events as recorded in a large administrative database 2008 through 2010. Transfusion 2012, 52:2113-2121.
33. Funk M.B., Gross N., Gross S., Hunfeld A., Lohmann A., Guenay S., et al. Thromboembolic events associated with immunoglobulin treatment. Vox Sang 2013, 105:54-64.
34. FDA Public Workshop: risk mitigation strategies to address procoagulant activity in immune globulin products. May 17, 2011. Available from:. Accessed October 8, 2013. http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/UCM258022.pdf.
35. Roemsch JR. Identification of activated factor XI as the major biochemical root cause in IVIg batches associated with thromboembolic events. Analytical and experimental approaches resulting in corrective and preventive measures implemented into the Octagam manufacturing process. Available from:. Accessed October 8, 2013. http://www.webmedcentral.com/article_view/2002.
36. Alving B.M., Tankersley D.L., Mason B.L., Rossi F., Aronson D.L., Finlayson J.S. Contact-activated factors: contaminants of immunoglobulins preparations with coagulant and vasoactive properties. JLab Clin Med 1980, 96:334-346.
37. Reinhart W.H., Berchtold P.E. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992, 339:662-664.
38. Eibl M.M. Intravenous immunoglobulins in neurological disorders: safety issues. Neurol Sci 2003, 24(Suppl 4):S222-S226.
39. Cantú T.G., Hoehn-Saric E.W., Burgess K.M., et al. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 1995, 25:228-234.
40. Centers for Disease Control and Prevention (CDC) Renal insufficiency and failure associated with immune globulin intravenous therapy-United States, 1985-1998. MMWR Morb Mortal Wkly Rep 1999, 48:518-521.
41. Zhang R., Szerlip H.M. Reemergence of sucrose nephropathy: acute renal failure caused by high-dose intravenous immune globulin therapy. South Med J 2000, 93:901-904.
42. Welles C.C., Tambra S., Lafayette R.A. Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion. Am J Kidney Dis 2010, 55:148-151.
43. Burks A.W., Sampson H.A., Buckley R.H. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. NEngl J Med 1986, 314:560-564.
44. Björkander J., Hammarström L., Smith C.I., Buckley R.H., Cunningham-Rundles C., Hanson L.A., et al. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. JClin Immunol 1987, 7:8-15.
45. Rachid R., Bonilla F.A. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. JAllergy Clin Immunol 2012, 129:628-634.
46. Sundin U., Nava S., Hammarström L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998, 112:341-346.
47. Eijkhout H.W., van den Broek P.J., van der Meer J.W. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med 2003, 61:213-217.
48. Ahrens N., Höflich C., Bombard S., Lochs H., Kiesewetter H., Salama A. Immune tolerance induction in patients with IgA anaphylactoid reactions following long-term intravenous IgG treatment. Clin Exp Immunol 2008, 151:455-458.
49. Horn J., Thon V., Bartonkova D., Salzer U., Warnatz K., Schlesier M., et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol 2007, 122:156-162.
50. Pintova S., Bhardwaj A.S., Aledort L.M. IVIG-a hemolytic culprit. NEngl J Med 2012, 367:974-976.
51. Daw Z., Padmore R., Neurath D., Cober N., Tokassy M., Desjardins D., et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008, 48:1598-1601.
52. Kahwaji J., Barker E., Pepkowitz S., Klapper E., Villicana R., Peng A., et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009, 4:1993-1997.
53. Morgan S., Sorensen P., Vercellotti G., Zantek N.D. Haemolysis after treatment with intravenous immunoglobulin due to anti-A. Transfus Med 2011, 21:267-270.
54. FDA Safety Communication: Updated information on the risks of thrombosis and hemolysis potentially related to administration of intravenous, subcutaneous and intramuscular human immune globulin products 11-13-2012. Available from:. Accessed July 29, 2013. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm327934.htm.
55. Oncley J.L., Melin M., Richert D.A., Cameron J.W., Gross P.M. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and β-1 lipoprotein into subfractions of human plasma. JAm Chem Soc 1949, 71:541-550.
56. Privigen [prescribing information] 2013, Revised February 2013, CSL Behring, King of Prussia, PA.
57. Dhainaut F., Guillaumat P.-O., Dib H., Perret G., Sauger A., de Coupade C., et al. In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations. Vox Sang 2013, 104:115-126.
58. Matsuda M., Hosoda W., Sekijima Y., Hoshi K., Hashimoto T., Itoh S., et al. Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders. Clin Neuropharmacol 2003, 26:306-311.
59. Baxley A., Akhtari M. Hematologic toxicities associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2011, 11:1663-1667.
60. Jarius S., Eichhorn P., Albert M.H., Wagenpfeil S., Wick M., Belohradsky B.H., et al. Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFalpha-dependent and Fc receptor-independent way. Blood 2007, 109:4376-4382.
61. Rizk A., Gorson K.C., Kenney L., Weinstein R. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion 2001, 41:264-268.
62. Steinberger B.A., Ford S.M., Coleman T.A. Intravenous immune globulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia. Am J Hematol 2003, 73:97-100.
63. Gerstenblith M.R., Antony A.K., Junkins-Hopkins J.M., Abuav R. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy. JAm Acad Dermatol 2012, 66:312-316.
64. Gardulf A., Hammarström L., Smith C.I. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991, 338:162-166.
65. Gardulf A., Andersen V., Björkander J., Ericson D., Frøland S.S., Gustafson R., et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995, 345:365-369.
66. Wasserman R.L. Common infusion-related reactions to subcutaneous immunoglobulin therapy: managing patient expectations. Patient Prefer Adherence 2008, 2:163-166.
67. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin N Am 2008, 28:779-802.
68. Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous igG vs intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol 2011, 11:532-538.
69. Skoda-Smith S., Torgerson T.R., Ochs H.D. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag 2010, 6:1-10.